摘要
泽布替尼是第二代布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase,BTK)抑制剂,于2019年11月15日经美国FDA批准上市,用于治疗既往接受过至少1项疗法的成年套细胞淋巴瘤(mantle cell lymphoma,MCL)患者。泽布替尼的选择性优于伊布替尼,患者耐受性良好,常见不良反应包括中性粒细胞减少、血小板减少、挫伤或瘀斑、上呼吸道感染和皮疹等。本文主要介绍泽布替尼的作用机制、药动学、临床试验和安全性。
Zanubrutinib is the second-generation Bruton’s tyrosine kinase(BTK)inhibitor,which was approved by the U.S.FDA on November 15,2019 for the treatment of adult patients with mantle cell lymphoma(MCL)who have received at least one prior therapy.Zanubrutinib is more selective than ibutinib and is well tolerated with common adverse reactions including neutropenia,thrombocytopenia,bruising or petechiae,upper respiratory tract infections and rashes.The action mechanism,pharmacokinetics,clinical trials and safety of zanubrutinib were reviewed in this article.
作者
王春晖
张雪皎
吕迁洲
WANG Chun-hui;ZHANG Xue-jiao;LU Qian-zhou(Department of Pharmacy,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200032,China;Department of Hematology,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200032,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2021年第20期1836-1840,共5页
Chinese Journal of New Drugs
基金
上海市卫生计生系统重要薄弱学科建设项目(2016ZB0301)
上海市临床重点专科项目(shslczdzk06504)。
